Evaxion A/S (NASDAQ: EVAX) announced the completion of a one-year extension for its phase 2 trial evaluating personalized cancer vaccine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE